Podcasts about Bayer

On this episode of The Mark White Show, Dr. Diana Bitner, board certified OB GYN and Certified Menopause Society Practitioner, joins veteran news anchor and patient advocate Wendee Lee Curtis for an open conversation about moderate to severe hot flashes due to menopause. They discuss what these symptoms can feel like, why many women are unprepared for their impact, and the importance of talking with a healthcare professional. The conversation also includes information about Lynkuet® (elinzanetant), a newly FDA approved, hormone free treatment option for moderate to severe hot flashes due to menopause. This episode focuses on awareness, understanding, and informed conversations between women and their doctors. These guests appear on behalf of Bayer and have been compensated for their time.

Today's guest is Kun He, Lead Scientific Advisor at Bayer Crop Science. He joins Emerj Editorial Director Matthew DeMello to discuss how AI is transforming human talent and workforce development in agricultural manufacturing, balancing data-driven efficiency with the irreplaceable role of human gut instinct. Kun also explores practical takeaways, such as integrating genotyping and phenotyping data to accelerate crop-breeding workflows, empowering breeders to drive "step change" innovations, and treating AI as a co-pilot to check biases while prioritizing customer needs for blockbuster R&D outcomes. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the 'AI in Business' podcast!

Der deutsche Chemiekonzern hat sich mit dem Kauf von Monsanto milliardenschwere Klagen aufgehalst. Doch mittlerweile zeigt sich auch, welche Macht Bayer damit erhalten hat.

S5E13 Future of AI-Powered Consumer Insights with Trevor Sumner & Stan SthanunathanIn Season 5, Episode 13 of The Retail Razor Show, hosts Ricardo Belmar and Casey Golden tackle one of retail's biggest blind spots in consumer insights: the consumer sentiment gap. For decades, brands relied on surveys to understand shoppers. But what people say doesn't always match what they do.Enter AI-powered shopper insights!Joining the conversation are Trevor Sumner (CEO of i-Genie AI) and Stan Sthanunathan (Executive Chairman of i-Genie AI, former EVP at Unilever and VP at Coca-Cola). Together, they reveal how billions of unfiltered signals — from searches, reviews, and social posts — can be transformed into real-time, actionable consumer insights that reshape retail decision-making.What You'll Learn in This Episode:Why traditional consumer surveys are breaking downHow AI and natural language processing uncover real customer behaviorThe role of empathy vs sympathy in understanding consumersHow disruptor brands are reshaping competitive landscapesWhy augmented intelligence (AI + human insight) is the future of retail strategy and consumer insightsSubscribe to the Retail Razor Podcast Network: https://retailrazor.com/Subscribe to our Newsletter: https://retailrazor.substack.comSubscribe to our YouTube channel: https://bit.ly/RRShowYouTubeAbout our GuestsTrevor Sumner, CEO, i-Genie.AI - https://www.linkedin.com/in/trevorsumner/Trevor is a NYC-based entrepreneur, product and marketing executive and recognized startup advisor and angel. Trevor is the CEO at i-Genie.ai, the leading AI platform for consumer insights, revolutionizing an industry that had been dominated with antiquated survey methodologies by synthesizing tens of billions of searches, social and video posts, ratings and reviews and market data for industry leaders like Kenvue, Unilever, Coca-Cola, Bayer, Clorox and more.Previously, Mr. Sumner was Head of AI and Data Platform products for Raydiant, a leading VC-backed digital experience platform that is transforming over 250,000 digital touch points across 4,500 clients with AI, computer vision and data.Mr. Sumner came to Raydiant when it acquired Perch, a recognized leader in in-store Product Engagement Marketing, interactive retail displays and augmented reality, where Mr. SUmner served as CEO. Perch was named a Top Tech Company to Watch by Forbes, a Top 10 Retail Technology company by CIO Review and has won numerous Clio, Fast Company, Edison, Bloomberg and Digi awards.Stan Sthanunathan, Executive Chairman, i-Genie.AI - https://www.linkedin.com/in/stan-sthanunathan-1ab4035/Stan Sthanunathan joined Unilever in July 2013 as Executive Vice President of Consumer & Market Insights. As chief provocateur, he headed up the insights function globally based in London. He retired from Unilever on June 1, 2021.Post retirement he has started an AI/ML enabled company called i-Genie.AI focused on delivering near real time insights and ideas to help business identify Next Big Thing. Prior to joining Unilever, he was Vice President of Marketing Strategy & Insights for The Coca-Cola Company in Atlanta, heading up the function on a global basis.Stan co-authored a paper on Building an Insights Engine that was published in Harvard Business Review, Sept 2016. He has also co-authored a book titled AI for Marketing and Product Innovation.He was awarded Lifetime Achievement award at TMRE 2022 event.Chapters:00:00 Previews 01:23 Show Intro 04:43 The Consumer Sentiment Gap 05:37 Welcome Trevor Sumner & Stan Sthanunathan 06:30 Backgrounds of Trevor and Stan 09:11 Challenges in Understanding Consumers 16:58 The Evolution of Influencers 18:32 Limitations of Surveys and the Need for AI 25:46 Augmented Intelligence: AI + Human Insight 31:46 Challenges in CPG Innovation 33:02 Innovate: A Data-Driven Product 34:42 AI and Predictive Analytics 36:21 Democratizing Data Access 38:07 Mindset Shift for Rapid Actions 40:46 Adopting AI in CPG 48:16 Retailers and Data Utilization 52:59 Future of Brand Understanding 57:23 Conclusion and Contact Information 58:15 Show CloseMeet your hosts, helping you cut through the clutter in retail & retail tech:Ricardo Belmar is an NRF Top Retail Voices for 2025 & a RETHINK Retail Top Retail Expert from 2021 – 2025. Thinkers 360 has named him a Top 10 Retail, & AGI Thought Leader, a Top 50 Management, Transformation, & Careers Thought Leader, a Top 100 Digital Transformation & Agentic AI Thought Leader, plus a Top Digital Voice for 2024 and 2025. He is an advisory council member at George Mason University's Center for Retail Transformation, and the Retail Cloud Alliance. He was most recently the director partner marketing for retail & consumer goods in the Americas at Microsoft.Casey Golden, is CEO of Luxlock, a RETHINK Retail Top Retail Expert from 2023 - 2025, and a Retail Cloud Alliance advisory council member. Obsessed with the customer relationship between the brand and the consumer. After a career on the fashion and supply chain technology side of the business, now slaying franken-stacks and building retail tech! Currently, Casey is the North America Leader for Retail & Consumer Goods at CI&T.Includes music provided by imunobeats.com, featuring Overclocked, and E-Motive from the album Beat Hype, written by Heston Mimms, published by Imuno.

Pepe Baynat analiza en Radio Intereconomía la situación general de los mercados. En el plano macro, destaca el buen momento del IBEX 35 en máximos históricos, que continúa con la tendencia alcista que viene marcando este año, mostrando fortaleza frente a otros mercados europeos. En Wall Street, pese a las caídas puntuales del sector tecnológico, el S&P 500 sigue mostrando una estructura sólida y podría volver a testear máximos si mantiene los soportes clave. Pepe Baynat insiste en la importancia de identificar soportes, resistencias y tendencias antes de tomar decisiones, señalando que muchos valores han subido con fuerza y pueden estar en fases de consolidación o corrección. El experto recomienda cautela en acciones que han tenido fuertes revalorizaciones (como Leonardo o McKesson) y advierte del riesgo de “arranques en falso” en compañías que vienen de caídas muy profundas, como Bayer, Stellantis o Nokia, donde pueden darse rebotes técnicos pero con alta volatilidad. Para estrategias de medio y largo plazo, sugiere paciencia en valores castigados pero con potencial de recuperación, como Cellnex, siempre que respeten ciertos niveles técnicos. En otros casos, plantea operaciones de corto plazo muy condicionadas a stops claros. El mercado sigue ofreciendo oportunidades, pero exige disciplina, gestión del riesgo y no dejarse llevar únicamente por subidas recientes o movimientos emocionales.

Der 14. Spieltag endete mit einer Fast-Sensation. Mainz lag bei den Bayern vorne, freut sich aber trotzdem über das 2:2. Auch Borussia Dortmund ist mit dem 1:1 in Freiburg wegen der langen Unterzahl nicht unzufrieden. Außerdem siegte der VfB Stuttgart deutlich in Bremen. DAS Tor des Wochenendes gelang jedoch dem Leverkusener Martin Terrier beim Sieg gegen den 1. FC Köln. Luise Kropff und Tobi Schäfer haben für die Aktion ein neues Wort aufgetan, das in das Fußball-Lexikon eingetragen werden muss. Außerdem sprechen die beiden natürlich auch über den Boykott der aktiven Fanszene als Protest gegen die Kontrollen der Polizei vor dem Nachbarschaftsduell zwischen Bayer und dem FC. Dazu geht es auch noch um andere wichtige Siege am 14. Spieltag: Eintracht Frankfurt bedankt sich bei Ritsu Doan und seiner feinen Einzelleistung, die zum Sieg gegen Augsburg reichte. FCA-Trainer Manuel Baum hat sich durch das Spiel allerdings aus anderen Gründen eine Diskussion mit seiner Tochter eingehandelt. Dem FC St. Pauli gelang nach 10 sieglosen Partien in der Liga der lang ersehnte Sieg gegen Heidenheim durch zwei Tore von Martijn Kaars und Wolfsburg arbeitet sich unter Interims-Trainer Daniel Bauer durch das 3:1 in Gladbach aus der Krise. Wird die Bauerlösung nun zur Dauerlösung? Und ist die TSG Hoffenheim tatsächlich reif für die Champions League? Das 4:1 gegen den Hamburger SV war der nächste beeindruckende Offensiv-Auftritt der Kraichgauer. Und beeindruckt hat auch Union Berlin. Beim etwas überraschenden Heimsieg gegen RB Leipzig konnten die Köpenicker endlich mal wieder über Stürmer-Tore jubeln. Das alles und mehr sind die Themen in der neuen Folge des Bundesliga Updates. Viel Spaß beim Hören und danke fürs Dabei-Sein!

Bayer Leverkusen schlägt den FC im Derby verdient. Die TSG Hoffenheim mausert sich zum CL-Kandidaten. Eintracht Frankfurt gewinnt zwar, überzeugt aber nicht. Wolfsburg schlägt Gladbach und St. Pauli holt wichtige Zähler im Abstiegskampf!

En Capital Intereconomía hemos seguido en directo la apertura del Ibex 35 y del resto de bolsas europeas, en una jornada de tono positivo y con signo mixto en los principales mercados internacionales. Entre los protagonistas del Ibex, destacaron las subidas en Repsol, apoyada por el nuevo informe de la Agencia Internacional de la Energía (AIE), que prevé que el consumo de petróleo siga creciendo hasta 2050, y en IAG, que consolidó su rebote tras las recientes caídas. En el mercado continuo, sobresalieron las compañías ligadas a la tecnología y la energía, mientras en Europa, las farmacéuticas captaron la atención con Bayer superando las previsiones de beneficios gracias a la fuerte demanda de nuevos medicamentos. En el análisis de mercados, Juan Enrique Cadiñanos subrayó que el foco de los inversores sigue puesto en la inteligencia artificial, con fuertes expectativas en torno a AMD, Infineon y Foxconn, pese a las recientes desinversiones en Nvidia. El experto explicó que, aunque el Dow Jones marca récord tras el fin del cierre de Gobierno en EE.UU., la tecnología muestra cierta corrección, reflejo de una rotación temporal hacia sectores más cíclicos. Cadiñanos señaló que el mercado podría mantener un tono lateral alcista a corto plazo, a la espera de los próximos datos macro y de la evolución de los rendimientos de los bonos, mientras la inteligencia artificial y la energía se mantienen como temas dominantes de inversión. El programa cerró con el consultorio de bolsa junto a Miguel Méndez, analista independiente, quien respondió a las consultas de los oyentes sobre valores tecnológicos, energéticos y estrategias defensivas ante la volatilidad de final de año.

99 Prozent aller Regeln sind abgeschafft, die Konzernaristokratie entmachtet. Bayer CEO Bill Anderson lässt die Teams entscheiden. Kann diese radikale Transformation gelingen? Weiterführende Links: Fallstudie zur Bayer-Transformation von Diemar Palan Interview mit Gary Hamel Die Bücher von Gary Hamel heißen unter anderem „Competing for the Future“ und „Das Ende des Managements“. „Humanocracy“ ist sein neuestes Buch. Zum manager magazin Abo Podcast "Wegen guter Führung - Der ehrliche Führungspodcast" Antonia Götsch, Chefredakteurin des Harvard Business managers, meldet sich alle zwei Wochen mit „Wegen guter Führung“. Sie spricht mit anderen Führungskräften und Expert:innen aus der Wissenschaft. Ehrlich, fundiert, offen und auch mal lustig. Sie teilt, was sie selbst gelernt hat, woran sie scheitert, und versucht auch ihren Gästen zu entlocken, was sie sonst nur ihren Vertrauten verraten. Hier geht es zu den Folgen Dieser Podcast wurde produziert von Felix Klein und Nele Geiger.+++ Alle Infos zu unseren Werbepartnern finden Sie hier. Die manager-Gruppe ist nicht für den Inhalt dieser Seite verantwortlich. +++ Alle Podcasts der manager Gruppe finden Sie hier. Mehr Hintergründe zum Thema erhalten Sie bei manager+. Jetzt drei Monate für nur € 10,- mtl. lesen und 50% sparen manager-magazin.de/abonnieren Informationen zu unserer Datenschutzerklärung.

Bayer Verango - Episódio 5: Resultados de campo: números que falam mais alto

#NUFC #UCL #ChampionsLeague #HWTL #NewcastleUnited #PremierLeague #EPL #bayerleverkusen #bayer #bundesliga #leverkusen

Wir haben Robert und den Bayer auf dem Weihnachtsmarkt getroffen und was sollen wir sagen six seven Leute.

Die Kunst der Arbeitgebermarkenbildung Gast: Marcus MerheimEmployer Branding, Marketing, internationale Erfahrungen, HR, Digitalisierung, Social Media, Unternehmensidentität, Karriere, Alumni, StudienerfahrungenSummaryIn dieser Episode des Dualen Studios spricht der ehemalige Fontys-Student Marcus Merheim über seine Karriere im Bereich Marketing und Employer Branding. Er teilt seine Erfahrungen aus dem Studium, seine internationale Zeit in Hongkong und die Gründung seines Unternehmens Human Employer Marketing. Marcus betont die Bedeutung von Employer Branding für Unternehmen und wie wichtig es ist, die Identität und Kultur eines Unternehmens zu verstehen, um Talente anzuziehen und zu halten. Er diskutiert auch die Rolle von Social Media und Digitalisierung in der heutigen Arbeitswelt sowie die Herausforderungen und Chancen, die sich daraus ergeben.TakeawaysMarcus Merheim hat an der Fontys von 2002 bis 2006 Marketing studiert.Die internationale Perspektive und Projektarbeit waren entscheidend für seine Entwicklung.Er sammelte Erfahrungen bei Porsche und Bayer, bevor er nach Hongkong ging.In Hongkong arbeitete er an innovativen Projekten im Bereich Technological Market Research.Marcus gründete 2021 Human Employer Marketing, um Unternehmen bei der Arbeitgebermarkenbildung zu unterstützen.Employer Branding ist entscheidend für die Anwerbung und Bindung von Talenten.Die Identität eines Unternehmens muss klar kommuniziert werden, um attraktiv zu sein.Remote-Arbeit hat sich als effektives Arbeitsmodell etabliert.Social Media spielt eine wichtige Rolle im Employer Branding.Zukünftige Trends im Employer Branding erfordern ganzheitliche Markenführung.TitlesDie Reise eines Alumni: Von der Fontys zur internationalen KarriereEmployer Branding: Die Kunst der ArbeitgebermarkenbildungSound bites"Employer Branding ist ein strategisches Fundament.""Don't fall into the AI trap.""Arbeiten kann was richtig Schönes sein."Chapters00:00 Einführung und persönliche Hintergründe03:06 Studium und erste berufliche Erfahrungen06:05 Internationale Erfahrungen in Hongkong09:10 Rückkehr nach Deutschland und Einstieg in HR-Themen11:44 Gründung von Human und aktuelle Tätigkeiten14:47 Kunden und Projekte von Human17:40 Digitalisierung und Remote-Arbeit23:47 Vertrauen und moderne Arbeitsmodelle25:43 Employer Branding: Definition und Bedeutung30:32 Strategische Schritte im Employer Branding35:15 Die Rolle von Social Media und Corporate Influencern38:42 Talentgewinnung und die Candidate Journey40:02 Umgang mit negativen Bewertungen41:27 Messbarkeit von Employer Branding Maßnahmen43:47 Zukunftstrends im Employer Branding46:15 Tipps für Absolventen und Berufseinsteiger

In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Lea Oetjen über einen Dämpfer für Thyssenkrupp, einen Rekord für den Silberpreis und den wohl größten Börsengang aller Zeiten. Außerdem geht es um Bayer, Rheinmetall, Renk Group, Hensoldt, Applovin, Warner Bros. Discovery, Mercedes-Benz, Fidelity, Alphabet, Nvidia, BMW, Campbell Soup Company, The Trade Desk, iShares MSCI USA ETF (WKN: A0YEDU), Vanguard S&P 500 ETF (WKN: A2PFN2), iShares Edge MSCI USA, Momentum Factor ETF (WKN: A2AP36), Xtrackers MSCI World Momentum (WKN: A1103G) und SPDR MSCI World ETF (WKN: A2N6CW). Die aktuelle "Alles auf Aktien"-Umfrage findet Ihr unter: https://www.umfrageonline.com/c/mh9uebwm Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Erfahre hier mehr über unseren Partner Scalable Capital - dem Broker mit einem der besten YouTube-Kanäle zu Aktien & Investments.  BMW hat neuen CEO. NVIDIA hat neue Exportrechte (oder auch nicht). Robert Gagliardi hat paar Millionen mehr. Bayer performt, Evotec & Thyssenkrupp nicht. EssilorLuxottica leidet unter Google-Konkurrenz. Ares goes S&P 500. Medline goes IPO. OpenAI goes focus. Was passt besser zu Weihnachten als Schoko- & Lebensmittel? Lindt (WKN: 859568) & Coca Cola (WKN: 850663) haben die richtige Strategie. Mondelēz (WKN: A1J4U0) & Nestlé (WKN: A0Q4DC) haben's nicht so leicht. Coca-Cola Consolidated (WKN: 860150) boomt. Diesen Podcast vom 10.12.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

En Capital Intereconomía hemos seguido en directo la apertura del Ibex 35 y del resto de bolsas europeas, en una jornada de tono positivo y con signo mixto en los principales mercados internacionales. Entre los protagonistas del Ibex, destacaron las subidas en Repsol, apoyada por el nuevo informe de la Agencia Internacional de la Energía (AIE), que prevé que el consumo de petróleo siga creciendo hasta 2050, y en IAG, que consolidó su rebote tras las recientes caídas. En el mercado continuo, sobresalieron las compañías ligadas a la tecnología y la energía, mientras en Europa, las farmacéuticas captaron la atención con Bayer superando las previsiones de beneficios gracias a la fuerte demanda de nuevos medicamentos. En Capital Intereconomía hemos seguido en directo la apertura del Ibex 35 y del resto de bolsas europeas en una sesión marcada por la cautela de los inversores a la espera de Jerome Powell. En el análisis de mercados, Manuel Pinto, analista de XTB, ha abordado el repunte del IPC en China, que marca máximos de dos años, junto a la persistente deflación industrial. En el plano corporativo, se ha comentado la fusión entre Anglo American y Teck, mientras que Sacyr ha caído en bolsa tras la colocación del 5% de la compañía con un descuento del 6,5%. El mercado entra en la recta final del año, con el debate abierto sobre una posible rotación sectorial. La jornada ha finalizado con el Consultorio de Bolsa junto a Miguel Méndez, analista independiente.

Die deutsche Autoindustrie steckt in einer Krise mit fallenden Verkäufen, Lohnkürzungen und schlechtem Ruf, doch die Aktien zeigen ein anderes Bild. Ich erkläre dir die langen Abwärtstrends der Hersteller und warum selbst ein KGV unter 5 kaum Anleger anzieht. Außerdem erfährst du am Beispiel von Bayer, wann ein echter Einstiegszeitpunkt erkennbar ist. Vereinbare jetzt dein kostenfreies Strategiegespräch: https://jensrabe.de/Q4Termin25 Trage dich hier in meinen täglichen kostenfreien Newsletter ein https://jensrabe.de/Q4NewsYT25

Among the many challenges that corn growers face every growing season, corn rootworms can be among the most damaging. In this Managing for Profit, DEKALB corn portfolio lead Matthew Strubhart discusses strategies for protecting yield from this costly pest.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

“ It's like a group of misfits gathering behind the bleachers after school. And we're all weird and no one wants to hang out with us. So we get together and we tell stories together.” This episode features Bryce Bayer who played Munkustrap in the 2025 Music Theatre Heritage production of CATS in Kansas City. Bryce shares insights on his unique experience with this non-traditional version, including the use of minimal characters, a hip-hop and jazz infusion, and the fascinating concept of a ritualistic book club. Learn about Bryce's journey from no prior CATS experience to embracing and performing in this innovative interpretation. 03:01 The Unique 2025 Production of Cats 05:24 Rehearsal Insights and Podcast Discovery 08:09 Character Dynamics and Conceptual Approach 33:30 Creative Interpretations 36:04 Excitement for Traditional and Non-Traditional Productions 39:14 Innovative Stage Design and Props 43:02 Rapid Fire Check out Bryce on Instagram: @bbayer7 Check out MTH on Social Media: @MTHTheater ⁠⁠⁠ Check out MTH's website: ⁠musictheaterheritage.com⁠ Check out The Music Man on Tour: themusicmantour.com Produced by: ⁠⁠⁠⁠⁠⁠Alan Seales⁠⁠⁠⁠⁠⁠ & ⁠⁠⁠⁠⁠⁠Broadway Podcast Network⁠⁠⁠⁠⁠⁠ Social Media: @⁠⁠⁠⁠⁠⁠TheWrongCatDied Learn more about your ad choices. Visit megaphone.fm/adchoices

LISTEN and SUBSCRIBE on:Apple Podcasts: https://podcasts.apple.com/us/podcast/watchdog-on-wall-street-with-chris-markowski/id570687608 Spotify: https://open.spotify.com/show/2PtgPvJvqc2gkpGIkNMR5i WATCH and SUBSCRIBE on:https://www.youtube.com/@WatchdogOnWallstreet/featured  The administration is rolling out another $12 billion in “Farm Aid”, supposedly to help farmers hurt by the ongoing trade war—yet most of that cash, just like in 2018 and 2019, is poised to flow straight through the farmers and into the pockets of Big Ag giants like Bayer and Monsanto. With China falling far short of its promised soybean purchases and America doubling down on the same broken agricultural policies—ethanol mandates, corporate consolidation, and subsidizing bad incentives—we're once again treating symptoms instead of fixing the system. From misguided crop priorities to farmland mismanagement, Chris calls out the waste, the politics, and the corporations cashing in while taxpayers foot the bill.

In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Lea Oetjen über den Magnum-Börsengang, ein Kursfeuerwerk bei Wave Life und das große Warten auf die Fed-Sitzung. Außerdem geht es um Unilever, Klöckner & Co, Worthington Steel, Rheinmetall, Renk, Thyssenkrupp Marine Systems, Bayer, Confluent, IBM, Marvell Technology, Carvana, Nvidia, Warner Bros Discovery, Netflix, Paramount Skydance, RTL Group, Evonik Industries, Freenet, Ströer, BASF, iShares S&P 500 Communication Sector ETF (WKN: A2JQ2H) und Xtrackers MSCI USA Communication Services ETF (WKN: A2QGNF). Folgt ihr uns schon bei Instagram? Wenn nicht, könnt ihr das hier nachholen: www.instagram.com/alles_auf_aktien Die aktuelle "Alles auf Aktien"-Umfrage findet Ihr unter: https://www.umfrageonline.com/c/mh9uebwm Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Newcastle picked up an important 2-1 home win over Burnley, with goals from Bruno Guimarães and Anthony Gordon setting the tone for a huge week ahead.In this episode of Talk of the Toon, we break down:Reaction to the 2-1 victory at St James' ParkThe growing influence of Bruno and Gordon in NUFC's attackA major European test next as Newcastle travel to Bayer LeverkusenEarly thoughts on the upcoming Tyne-Wear derby against SunderlandWhat this crucial run of fixtures means for confidence, momentum, and Eddie Howe's plansA big win, a European challenge on the road, and derby day looming - we assess where NUFC stand heading into a defining week. Hosted on Acast. See acast.com/privacy for more information.

Welcome back to The Bundesliga Show! In this episode, the lads take you through the major talking points from Matchday 13 in the Bundesliga 2025/26! On Friday night, Gladbach edged out Mainz in the hosts' first match after the sacking of Bo Henriksen. A comical own goal by Danny da Costa was enough to seal three points for the in-form guests in a 1-0 win.On Saturday, FC Bayern thrashed Stuttgart in the Sued Derby 5-0. An opener from Laimer was followed up by a third Bundesliga hattrick of the season for Harry Kane, this time off the bench. Leipzig went one better in the Topspiel, embarrassing struggling Frankfurt 6-0 at the Red Bull Arena. Yan Diomande scored a hattrick in the second half, adding to goals from Harder, Raum and Baumgartner. Augsburg responded to the sacking of Sandro Wagner by easing past Leverkusen 2-0 in impressive fashion, and Heidenheim made it back-to-back wins thanks to a last minute Schimmer winner. On Sunday, the Nord Derby returned to the Bundesliga for the first time in 8 seasons as Werder Bremen visited Hamburg for what was a memorable clash. In the backdrop of a magificent atmosphere from both set of fans, the game burst into life thanks to a Jens Stage strike on the stroke of half time. The second half was a classic with Lokonga and Vuskovic strikes putting HSV ahead. Justin Njinmah levelled up before a famous Youssef Poulsen winner sparked huge celebrations for the home side. The hosts held out for a famous 3-2 win to continue their impressive Hinrunde under Merlin Polzin. Today the key matches include:Hamburger SV vs SV Werder BremenVfB Stuttgart vs FC Bayern MuenchenRB Leipzig vs Eintracht FrankfurtFC Augsburg vs Bayer 04 Leverkusen1. FC Heidenheim vs SC Freiburg Which was your favourite match of the week?Which players did you enjoy the most over this match day?Which team will be the most disappointed with their result?

Dr. Pedro Barata and Dr. Ravin Garg discuss strategies to increase trial representation, including leveraging trial navigators and prioritizing pragmatic trial models, as featured in the ASCO Educational Book article, "Practical Guide to Clinical Trial Accessibility: Making Trial Participation a Standard of Care." TRANSCRIPT Dr. Pedro Barata: Hello, and welcome to By the Book, a podcast from ASCO featuring compelling perspectives from authors and editors of the ASCO Educational Book. I'm Dr. Pedro Barata. I am a medical oncologist at University Hospital Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I am also the associate editor of the ASCO Educational Book. We know that in recent years, the oncology community has increasingly prioritized the need to modernize clinical trial eligibility, reduce patient burden, and enhance diversity in trial participation. On that note, today we will be speaking about ways to enhance access to clinical trials with Dr. Ravin Garg. He is a hematologist oncologist at Maryland Oncology Hematology and also an assistant professor of oncology at Johns Hopkins Hospital in Baltimore. Dr. Garg is also the co-author of a fantastic paper in the ASCO Educational Book titled, "Practical Guide to Clinical Trial Accessibility: Making Trial Participation a Standard of Care."  Dr. Garg, welcome. Thanks for being here, and congrats on your paper. Dr. Ravin Garg: Thank you for having me, Pedro. I am excited to be here. Dr. Pedro Barata: [KI1]  Your paper is a wonderful, multidisciplinary piece that actually features perspectives from the different stakeholders, right? The patient advocacy, industry, community practice, and academia about these challenges in making trials more available. This podcast is a wonderful platform. It reaches out to a lot of folks within our community. So, I will start by asking you the obvious. Why do you think it is a must read for our community, for our listeners? Dr. Ravin Garg: So Pedro, thanks again for inviting me. You do a great job with these podcasts.  So, I think first and foremost, oncologists right now are under a lot of stress, just in terms of clinical volume. There is concern for research money, and how we get the best care for our patients. So I think this article is very important because it helps bring together, as you had mentioned, the stakeholders throughout academic to community practice and everywhere in between, and try to find how, as a team with different oncologists who partake in different aspects of oncology, can come together to streamline the process to try to get our patients on trials, or certainly have them have availability of trials, just if they are interested in going on them. Being in practice, we have had several challenges that we can talk about throughout this podcast, but I think it is a very important paper because it recognizes that at the end of the day, it takes a team effort for all of us in academics, community, industry, and pharmaceuticals to really come together as a team to really help put forth the trials for our patients. Dr. Pedro Barata: So, from the perspective of a community oncologist, how do you put together, or maybe you can describe some of the challenges that you see to increase trial participation in the community? Dr. Ravin Garg: Yes, Pedro, that is a great question, and it is something that I keep on thinking about and trying to find ways to be better at it myself. But I will say some of the challenges as a community doctor that I have seen for myself and talking to other colleagues. Number one, I do think there is a lot of stress on doctors in the community in general, Pedro. Oftentimes we are tasked to see a wide smorgasbord of patients, so we may not have the luxury of being a specialist in any particular tumor subtype. Like oftentimes, we will have to see lung cancer, the next one will be breast cancer, the next one could be CML, the next one could be thrombocytopenia. And as you know better than I do, Pedro, the field in each one of these disciplines is changing so rapidly: molecular genomics, radioligand treatments, different imaging tests, MRD testing for some of our hematologic malignancies. And I think one challenge we have in community is just keeping up with the basics of Oncology 101. In the process of doing that, it can be very difficult to sometimes remember that we have very exciting trials available for our patients. So, I think a lot of it is the day in and day out of being an oncologist is so taxing at times that oftentimes a research trial is not the first thing in our head space when we see a patient. I think number two, Pedro, at least in the community, and perhaps this is with academics too, is that we are bombarded, I would say, by a lot of messaging these days. We have in-baskets to go through, labs to go through, things of that nature. And in the process of a patient visit, seeing them, doing an exam, taking a history, trying to go over the NCCN guidelines on best practice for how to manage their care, at least for me at times, it is very hard to remember, "Hey, there might be a great trial available, whether within our network or maybe partnering with an academic center." So getting through a day can be fraught with a lot of peril and just difficulties, I would say. And I would say number three, Pedro, at least as, you know, I am in a private practice where I do see a wide range of benign and malignant hematology and solid tumors, so I would not call myself a specialist. And I think the challenge with that, at least for trials, Pedro, is that when you are a specialist or perhaps you are focusing on a couple of disease subtypes, you become more of an authoritative voice in those types of tumors, and you might be more aware of the trials within your network or perhaps in proxy with an academic center that you can offer your patient. So I think when sometimes we spread ourselves too thin, it can be very hard to be a thought leader, if you will, in a particular subtype of a malignancy, let's say, and maybe not be aware of a trial that could be really well-suited for your patient. In terms of ideas that myself and colleagues have had in terms of helping mitigate against some of these, I would say, setbacks or issues in the practice for trial enrollment, some of the things we have talked about, Pedro, is, number one, is we do partner with academic centers. So we live here in Maryland. We have several really fantastic academic centers. So, you know, oftentimes, not just within our practice of Maryland Oncology Hematology, we have a lot of great trials available here too, for certain, but in addition to that, we will often times work with doctors at Georgetown, Johns Hopkins, and Maryland if they have a compelling trial that we do not have within our network. It is really of the patient's interest, Pedro, to reach out to them in a collaborative manner to see if they have a trial that might be really compelling for your patient. So I do find myself collaborating a lot with colleagues in, like talented like yourself in academics. You know, I think you do a lot of GU malignancies. So as an example, like partnering with colleagues who are GU experts and say, "Hey, we have a patient with stage IV renal cell. These are the standard options I know, but are there any trials that you might have available?" I think the other thing that has been very helpful for us is having navigators within research, Pedro. Like as an example, what has really helped the uptake of trial enrollment for our center in Annapolis is having a research navigator because often times what they can do is, a priori, Pedro, before you see the patient and you are kind of formulating a standard of care treatment plan perhaps, they might tug you on the shirt and say, "Hey, we have a great trial here through Sarah Cannon, or there might be something else out there." And being aware of that when you go into a patient's room really provides a nice arena, if you will, to go and say, "The standard of care is here, but hey, we have a trial option that might be well suited for you, maybe perhaps even better, that we can talk about, too." So having research support in the community is really a huge boon, I think, Pedro, for us to really increase our enrollment for patients onto trials. Dr. Pedro Barata: Yes, I really love that, Ravin. So, let me switch gears a bit. I would love for you to talk a little bit about patient advocacy because they do play a huge role in cancer, and they address many barriers. How do you think we should leverage the patient advocacy groups to reduce patient burden and maybe have them really leverage patient advocacies to improve representation in clinical trials? What do we think we can do more? Dr. Ravin Garg: Oh, Pedro, I think they are very critically important. As a clinical oncologist now, and I would say this is for anyone in the field of medicine, you are exactly right. I think patients are bombarded by information. There are a lot of things online, whether it be TikTok, Facebook, Google, Yahoo, and people really just have a lot of information given to them. And some of it is fact driven, and some of it is not, Pedro. And oftentimes, I do think there can be at times a mistrust with some medical personnel. I think we are in an era where we are seeing that to some degree with some attributes of medicine. And I think of it as an opportunity for education for the patient and for myself as a physician. And I think patient advocates, to your point, which was well taken, serve as a bridge to both. And what I mean is that, you know, patient advocates are wonderful. They are, I think, outstanding communicators. They almost are a neutral party, Pedro, where many patients feel that they are an independent source of information that is free of bias, if you will. They are there to provide support, emotional support, scientific support for patients so they can make an informed decision. So, in terms of our practice right now, patient advocates is something that we are evolving in that capacity, I would say, Pedro. I think now more than ever, having more people as bridges of communication with care providers along with patients is of critical importance. And I would venture a guess, and I think this has been published, where patient advocates really can help tremendously in familiarizing patients with trials and what they are all about and maybe clear up some misconceptions of what trials, what the mission of trials are. Because I do think some patients, at least I have had a few over the years, where when they hear the term trial, they almost think they are being experimented upon, when, in point of fact, they could really help advance their care. That messaging along the way for some can may be mixed up a little bit. And so I think patient advocates is a really great way to offer more information for patients with a source they find very independent and trustworthy, if you will. And it can really help expedite, and I think make a more fruitful conversation for care providers, whether academic or community, and they might be more open-minded in terms of enrolling onto a trial. Dr. Pedro Barata: Wonderful. Yes, I agree. I agree with you completely.  So let's focus a little bit now on the folks designing the studies. We usually call them the sponsors. It might be an academic sponsorship, if you will, but we can also have pharma being the sponsor of a study. The angle from an academic design, it is not necessarily the same as what happens when we have pharma. And from that angle, how do you think a more inclusive research can be promoted? Dr. Ravin Garg: Oftentimes with trials, I think keeping them simple, as simple as we can. And what I mean by that is, often times for trials, Pedro, even for care providers who are enrolling, it can be daunting when there are a lot of different things involved, particularly, let's say, for investigator sponsored, which are incredibly brilliant science, incredible, but it can be a little bit daunting for patients and even the referring physician to talk about getting translational specimens, imaging, traveling to certain centers to get scans and biopsies and even different diagnostic testing like PSMA testing for, you know, prostate cancer. And it can, I think, be very intimidating for patients in terms of what might be required of him or her to enter onto a trial. Like, "This is not what I signed up for. This is laborious. This is a full time job for me. Do I have to pay for parking to go to a city? Do I have to pay for these imaging tests? And do I have to stay in a place for my family to enroll onto a trial?" So I think keeping trials as simple as possible, but yet cull the data we need as investigators where we can really advance the care, hopefully get approval for a drug, but also learn more about the medication and how it works for our patients. So I think simplifying language for trial is very important. I know when I have gone over studies for patients, Pedro, if it is a voluminous amount of information, they can right away get very intimidated. "Like, oh my goodness, this is like a term paper for college again," you know? I am joking, but you know, keeping language simplified is very important, I think, number one. And I feel that sometimes when they are asked to do a lot of different diagnostic testing, which is very important for translational work, I 100% understand, but I do think sometimes patients can get a little bit off put, if you will, and frustrated with the whole process of doing it. The second thing for our patients, Pedro, that they have mentioned to us when we put them on trials, not just within our own site but elsewhere, is that it takes a lot of time in terms of collecting information, perhaps a washout period from their last standard of treatment prior to enrollment onto a study. Many patients, Pedro, as you know better than I do, are in maybe crisis in terms of their health and their cancer might be growing, promulgating out of control, and they worry about not being able to expeditiously start onto a treatment, onto a trial. So that can lead to a lot of frustration. And one thing that you brought up, which was outstanding for me, is the enrollment criterion for some of our patients is felt to be somewhat strict. We have had some patients who may have had a remote history of a stage I malignancy that was by all accounts in remission, you know, let's say 4 or 5 years in the past, and the risk of recurrence at this point would be incredibly low, but they may not be able to enter onto a study because of some stringent criterion put forth. And that can be a little bit frustrating. In fact, I have had one or two patients who, as an example, with kidney issues, but the GFR was about 60, like right near a cutoff that oftentimes, as you know, we use where you can get into trial or not. And you know, if they are at 58, as an example, and otherwise they are a picture of health, a great candidate for a trial that will likely advance their care, and if the entry criterion is too stringent, that might be a lost opportunity for all parties involved, all stakeholders, if you will. I do appreciate the criterion for entry onto studies cannot be too liberalized. You have to have a certain baseline, but there is a little bit of a gray area and tension, of sorts, if you will, where the patient has a comorbid illness that is a disqualifying offense, but in practicality, perhaps it shouldn't be, especially if they are motivated and there is an opportunity to really advance their care. We have run into, not often, but sometimes in the past, I should say, where patients have been very off put because we try to get them onto a study and there may have been a particular feature or attribute in their underlying care that they couldn't get onto it. So I think having a little bit more thoughtfulness, perhaps, in terms of entry criterion and practicality, if you will, I think would really help enrollment onto studies. Dr. Pedro Barata: Really well said. Is there anything else that you would like to tell our listeners before we wrap up the podcast today? Dr. Ravin Garg: I would say just macroscopically speaking, it is really an honor to be an oncologist. I think I speak for both of us. Anyone listening who is thinking about the field, it is tremendous. Just the research, the bravery of our patients, and the thoughtfulness of our scientists like Pedro and translationalists and clinical trialists is really awe inspiring. So I have really loved this field. I will say from a trial perspective, we really need to enter as many patients as we can onto trials because the science is so brilliant now, the genomic underpinnings of the tumor, we are making great strides as a team of clinicians and scientists, translationalists. So the more that we can get people onto trials and get approved drugs, it is going to help them out in the end. So I think it is such an important time for all of us to come together as a community, find the best way to help our patients out. And clinical trials have to be at the forefront of how we can continue to advance care for our patients. Dr. Pedro Barata: Yeah, no Ravin, I really agree with you. We really need to increase access to clinical studies, and actually your paper is a great step in that direction by raising awareness, bringing up solutions, and again, collaboration, collaboration, collaboration is really a multidisciplinary effort to accomplish that.  Thank you so much for sharing your fantastic thoughts and insights with us. Dr. Ravin Garg: Thank you, Pedro. I am- you do a wonderful job with these podcasts. I am really honored to meet you and to be part of this. Dr. Pedro Barata: And thank you to our listeners for your time today. I encourage you to check out Dr. Garg's article in the 2025 ASCO Educational Book. We will post a link to the paper in our show notes. And please join us again next month on By the Book for more insights on key advances and innovations that are shaping modern oncology. Thank you for your attention. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:          Dr. Pedro Barata   @PBarataMD    Dr. Ravin Garg Follow ASCO on social media:          @ASCO on X      ASCO on Bluesky     ASCO on Facebook       ASCO on LinkedIn       Disclosures:       Dr. Pedro Barata:   Stock and Other Ownership Interests: Luminate Medical   Honoraria: UroToday   Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon   Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas   Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck    Dr. Ravin Garg: Patents, Royalties, Other Intellectual Property: Creator, editor, and writer of hemeoncquestions.com  

En Capital Intereconomía hemos seguido en directo la apertura del Ibex 35 y del resto de bolsas europeas, en una jornada de tono positivo y con signo mixto en los principales mercados internacionales. Entre los protagonistas del Ibex, destacaron las subidas en Repsol, apoyada por el nuevo informe de la Agencia Internacional de la Energía (AIE), que prevé que el consumo de petróleo siga creciendo hasta 2050, y en IAG, que consolidó su rebote tras las recientes caídas. En el mercado continuo, sobresalieron las compañías ligadas a la tecnología y la energía, mientras en Europa, las farmacéuticas captaron la atención con Bayer superando las previsiones de beneficios gracias a la fuerte demanda de nuevos medicamentos. En el análisis de mercados, Juan Enrique Cadiñanos subrayó que el foco de los inversores sigue puesto en la inteligencia artificial, con fuertes expectativas en torno a AMD, Infineon y Foxconn, pese a las recientes desinversiones en Nvidia. El experto explicó que, aunque el Dow Jones marca récord tras el fin del cierre de Gobierno en EE.UU., la tecnología muestra cierta corrección, reflejo de una rotación temporal hacia sectores más cíclicos. Cadiñanos señaló que el mercado podría mantener un tono lateral alcista a corto plazo, a la espera de los próximos datos macro y de la evolución de los rendimientos de los bonos, mientras la inteligencia artificial y la energía se mantienen como temas dominantes de inversión. El programa cerró con el consultorio de bolsa junto a Miguel Méndez, analista independiente, quien respondió a las consultas de los oyentes sobre valores tecnológicos, energéticos y estrategias defensivas ante la volatilidad de final de año.

En Capital Intereconomía hemos seguido en directo la apertura del Ibex 35 y del resto de bolsas europeas, en una jornada de tono positivo y con signo mixto en los principales mercados internacionales. Entre los protagonistas del Ibex, destacaron las subidas en Repsol, apoyada por el nuevo informe de la Agencia Internacional de la Energía (AIE), que prevé que el consumo de petróleo siga creciendo hasta 2050, y en IAG, que consolidó su rebote tras las recientes caídas. En el mercado continuo, sobresalieron las compañías ligadas a la tecnología y la energía, mientras en Europa, las farmacéuticas captaron la atención con Bayer superando las previsiones de beneficios gracias a la fuerte demanda de nuevos medicamentos. En el análisis de mercados, Juan Enrique Cadiñanos subrayó que el foco de los inversores sigue puesto en la inteligencia artificial, con fuertes expectativas en torno a AMD, Infineon y Foxconn, pese a las recientes desinversiones en Nvidia. El experto explicó que, aunque el Dow Jones marca récord tras el fin del cierre de Gobierno en EE.UU., la tecnología muestra cierta corrección, reflejo de una rotación temporal hacia sectores más cíclicos. Cadiñanos señaló que el mercado podría mantener un tono lateral alcista a corto plazo, a la espera de los próximos datos macro y de la evolución de los rendimientos de los bonos, mientras la inteligencia artificial y la energía se mantienen como temas dominantes de inversión. El programa cerró con el consultorio de bolsa junto a Miguel Méndez, analista independiente, quien respondió a las consultas de los oyentes sobre valores tecnológicos, energéticos y estrategias defensivas ante la volatilidad de final de año.

Roberto Moro, analista de Apta Negocios, analiza los mercados en Capital Intereconomía.El consultorio parte de una visión optimista del mercado, con el Ibex 35 alcanzando nuevos máximos históricos y superando al resto de índices europeos. Aunque el DAX o el Eurostoxx aún se mueven en rangos laterales, la tendencia general en Europa y Estados Unidos es positiva, y se espera que también alcancen sus récords antes de fin de año, por lo que Roberto moro señala que “seguramente el DAX y el EURO STOXX lograrán alcanzar máximos históricos”. Pese al contexto geopolítico y las incertidumbres macroeconómicas, los mercados han mostrado una resiliencia notable, cerrando un ejercicio de fuertes subidas en los principales índices, lo que lleva a pensar que “el grueso del año ya está hecho”. En este escenario maduro de mercado, el análisis destaca la prudencia y la búsqueda selectiva de oportunidades. Se recomienda priorizar valores que estén rompiendo resistencias y con potencial alcista, frente a aquellos que ya han agotado gran parte de su recorrido. En Europa, compañías como Bayer y Stellantis cumplen esas condiciones técnicas, mientras que en EE. UU. se destacan AIG y Salesforce. La idea general es que, aunque el ciclo alcista podría prolongarse, el margen de subida es menor y aumenta la probabilidad de una corrección técnica natural tras tantos años de crecimiento sostenido. Por último, se subraya la importancia de mantener carteras equilibradas con valores defensivos como Iberdrola o Red Eléctrica, capaces de actuar como refugio ante eventuales correcciones. En conjunto, el análisis transmite un optimismo moderado, confiando en la fortaleza estructural de los mercados y en la continuidad del impulso alcista a corto plazo, pero reconociendo la madurez del ciclo y la necesidad de actuar con disciplina y gestión del riesgo en un entorno de máximos históricos.

Roberto Moro, analista de Apta Negocios, analiza los mercados en Capital Intereconomía.El consultorio parte de una visión optimista del mercado, con el Ibex 35 alcanzando nuevos máximos históricos y superando al resto de índices europeos. Aunque el DAX o el Eurostoxx aún se mueven en rangos laterales, la tendencia general en Europa y Estados Unidos es positiva, y se espera que también alcancen sus récords antes de fin de año, por lo que Roberto moro señala que “seguramente el DAX y el EURO STOXX lograrán alcanzar máximos históricos”. Pese al contexto geopolítico y las incertidumbres macroeconómicas, los mercados han mostrado una resiliencia notable, cerrando un ejercicio de fuertes subidas en los principales índices, lo que lleva a pensar que “el grueso del año ya está hecho”. En este escenario maduro de mercado, el análisis destaca la prudencia y la búsqueda selectiva de oportunidades. Se recomienda priorizar valores que estén rompiendo resistencias y con potencial alcista, frente a aquellos que ya han agotado gran parte de su recorrido. En Europa, compañías como Bayer y Stellantis cumplen esas condiciones técnicas, mientras que en EE. UU. se destacan AIG y Salesforce. La idea general es que, aunque el ciclo alcista podría prolongarse, el margen de subida es menor y aumenta la probabilidad de una corrección técnica natural tras tantos años de crecimiento sostenido. Por último, se subraya la importancia de mantener carteras equilibradas con valores defensivos como Iberdrola o Red Eléctrica, capaces de actuar como refugio ante eventuales correcciones. En conjunto, el análisis transmite un optimismo moderado, confiando en la fortaleza estructural de los mercados y en la continuidad del impulso alcista a corto plazo, pero reconociendo la madurez del ciclo y la necesidad de actuar con disciplina y gestión del riesgo en un entorno de máximos históricos.

Especialistas explicam o que faz de Verango® Prime da Bayer uma solução inovadora no manejo de nematóides

 Alissa Bayer graduated with her MBA from McCombs in 2004 and quickly launched Milk and Honey Spa. After over 20 years in business and 10 locations nationwide, in this episode she reflects back on the lessons she learned at McCombs, what it's been like to navigate changing social norms and how she hopes her business sparks joy in the wider community.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über das Microsoft-Barometer und seine Folgen, das Inditex-Luxusproblem und gute Stimmung bei Salesforce. Außerdem geht es um Eli Lilly, AbbVie, Johnson & Johnson, Novo Nordisk, AstraZeneca, Abbott Laboratories, UnitedHealth Group, Bristol Myers Squibb, Dexcom, Align Technology, ResMed, Hims & Hers, JD Health International, iRhythm Technologies, Pro Medicus, Oscar Health, Xtrackers MSCI World Health Care (WKN: A113FD), Amundi S&P World Health Care Screened (WKN: A3DSTC), Franklin Future of Health and Wellness (WKN A3EFKW), Global X Telemedicine & Digital Health (WKN A2QKQ1), Xtrackers MSCI Genomic Healthcare Innovation (WKN: DBX0R2), Agilent, Roche, Vertex, Microsoft, Meta, Alphabet, Amazon, Nvidia, Salesforce, SAP, Snowflake, Inditex, H&M, Next, LVMH, Hermès, Aumovio, TKMS, Hellofresh, Gerresheimer, Ottobock, Tonies, PSI Software, Verbio, LPKF, Stratec, Thyssenkrupp Nucera, Procredit, Amadeus Fire, Bayer, BASF, Corteva, Syngenta, Formycon und PNE. Die aktuelle "Alles auf Aktien"-Umfrage findet Ihr unter: https://www.umfrageonline.com/c/mh9uebwm Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

This episode covers: Cardiology This Week: A concise summary of recent studies DAPT: how short is too short Obesity and atrial fibrillation Milestones: COURAGE  Host: Emer Joyce Guests: Carlos Aguiar, Steffen Massberg, Prash Sanders Want to watch that episode? Go to: https://esc365.escardio.org/event/2178 Want to watch that extended interview on dual antiplatelet therapy (DAPT) and shortening its optimal duration, go to: https://esc365.escardio.org/event/2178?resource=interview   Disclaimer  ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Emer Joyce, Nicolle Kraenkel and Steffen Massberg have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Prashanthan Sanders has declared to have potential conflicts of interest to report: advisory board representative University of Adelaide, Medtronic, Boston Scientific, CathRx, Abbott and Pacemate as well as research grants for University of Adelaide: Medtronic, Abbott, Boston Scientific, Becton Dickson. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

En Capital Intereconomía hemos seguido en directo la apertura del Ibex 35 y del resto de bolsas europeas, en una jornada de tono positivo y con signo mixto en los principales mercados internacionales. Entre los protagonistas del Ibex, destacaron las subidas en Repsol, apoyada por el nuevo informe de la Agencia Internacional de la Energía (AIE), que prevé que el consumo de petróleo siga creciendo hasta 2050, y en IAG, que consolidó su rebote tras las recientes caídas. En el mercado continuo, sobresalieron las compañías ligadas a la tecnología y la energía, mientras en Europa, las farmacéuticas captaron la atención con Bayer superando las previsiones de beneficios gracias a la fuerte demanda de nuevos medicamentos. En el análisis de mercados, Juan Enrique Cadiñanos subrayó que el foco de los inversores sigue puesto en la inteligencia artificial, con fuertes expectativas en torno a AMD, Infineon y Foxconn, pese a las recientes desinversiones en Nvidia. El experto explicó que, aunque el Dow Jones marca récord tras el fin del cierre de Gobierno en EE.UU., la tecnología muestra cierta corrección, reflejo de una rotación temporal hacia sectores más cíclicos. Cadiñanos señaló que el mercado podría mantener un tono lateral alcista a corto plazo, a la espera de los próximos datos macro y de la evolución de los rendimientos de los bonos, mientras la inteligencia artificial y la energía se mantienen como temas dominantes de inversión. El programa cerró con el consultorio de bolsa junto a Miguel Méndez, analista independiente, quien respondió a las consultas de los oyentes sobre valores tecnológicos, energéticos y estrategias defensivas ante la volatilidad de final de año.

Antonio Aspas, socio de Buy & Hold Gestión de Activos, sigue de cerca el comportamiento en Philips, Bayer, Airbus, Rio Tinto, Safrán y el sector automovilístico, que vive un rebote claro.

Another of our special Themed Podcasts focussed on prostate cancer in China, supported by our Gold Partner, Bayer. We are joined as ever by our China Editor, Dr Yao Zhu (Fudan University Shanghai Cancer Centre), and also special guest Dr Yige Bao (SCU Xiamen Hospital). Not only do we learn about pandas in West China, but also some great highlights from the recent ESMO Annual Meeting in Berlin! Hosted as ever by Dr Renu Eapen and Prof Declan MurphyEven better on our YouTube channel 

Der von Felix auserkorene Weihnachtsmonat Dezember ist da – und unserem madrilenischen Exil-Meck-Pommer kommt's jetzt schon zu den Ohren raus. Doch was vernehmen wir da aus Madrid? Der Herr findet Spaß am Elf on the Shelf und legt beim Wichtelbasteln sogar selbst Hand an? Vielleicht geschehen also nicht nur in Whoville Weihnachtswunder, sondern auch bei unserem höchsteigenen Grinch. Oder heißt der in Spanien Gringo? Spanien ist vermutlich – auch nach dem Weggang von Xabi Alonso von Bayer – weiterhin ein gutes Stichwort für unsere heutige Spielanalyse: Ballspielverein 09 aus Dortmund gegen die Leverkusener Werkself(en). Sind doch mit Aleix García und Alejandro Grimaldo mindestens zwei der wichtigsten Leverkusener Akteure iberischer Natur am Werk. Naturgemäß auf den Punkt und messerscharf wird das Pokalspiel also weganalysiert, und die häufig provokante Frage, ob es denn ein unverdienter Sieg gewesen sei, mit einem „Ja, aber …“ beantwortet. Anschließend reden wir noch mit Hörer Yannik über die Last der späten Einwechslung – und darüber, was Kroos und Kroos eigentlich so in der Halbzeit eines herkömmlichen Spiels getrieben haben. Spoiler: nicht so wahnsinnig viel. Viel Spaß mit der neuen Folge! Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/luppentv) Für Werbe- und Partnerschaftsanfragen im Podcast EINFACH MAL LUPPEN meldet euch hier: werbung@studio-bummens.de

The Trump administration has weighed-in with their support of Bayer over the 67,000 cases where plaintiffs are suing the company over its Roundup brand and cases of cancer. KMOX Legal Analyst Brad Young offers details on what this may mean. Plus, copyright laws and infringement.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über starke Zahlen von Crowdstrike, Kurssprung bei Bayer und eine wilde Wende bei Bitcoin. Außerdem geht es um Ether, Intel, xLight, Meta, Boeing, Airbus, Marvell, Celestial AI, Nvidia, Broadcom, GitLab, Adobe, Workday, DocuSign, Apple, Microsoft, MongoDB, Credo Technology, Wacker Neuson, Doosan Bobcat, Hochtief, Hypoport, Hugo Boss, Rheinmetall, Nvidia, Lockheed Martin, Hensoldt, Renk, TKMS, VW, BMW, Mercedes-Benz, Continental, Porsche, Schaeffler, Daimler Truck, Bank of America, KeyCorp, PNC Financial Services, US-Bancorp, Truist Financial, Aon, Marsh & McLennan, Willis Towers Watson, Accenture, Cognizant, EPAM Systems, IBM, Twilio, DXC Technology, SAIC, Guidewire Software, Manhattan Associates, Pegasystems, Tyler Technologies, Labcorp, IQVIA, Certara und Siemens Energy. Die aktuelle "Alles auf Aktien"-Umfrage findet Ihr unter: https://www.umfrageonline.com/c/mh9uebwm Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Unser Partner Scalable Capital ist jetzt Bank und bietet euch dadurch noch bessere Konditionen. Unter anderem mit einem neuen Kreditangebot. Alle Infos dazu gibt's hier: https://de.scalable.capital/credit. Das Weiße Haus stellt sich hinter Bayer. Aktie hoch. Doosan Bobcat will Wacker Neuson. Aktie hoch. Boeing will Cash verdienen, MongoDB wächst stark. Aktien hoch. Nestlé könnte Blue Bottle verkaufen. ISS hat Problem in Hongkong. Dell spendet Milliarden. Marvell kauft Celestial. American Eagle Outfitters boomt. Action ist eine der krassesten Firmen, die in den letzten Jahren in Europa entstanden ist. Das Modell ist zwar langweilig, aber funktioniert. Die Börse wird grade vorsichtiger. Eine Chance, den Dip zu kaufen? 3i (WKN: A0MU9Q). Diesen Podcast vom 03.12.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

El analista de Apta Negocios revisa los títulos de Inditex, Cellnex, Hugo Boss, Indra, Bayer y ASML, entre otros

Bayer Crop Science is introducing a new herbicide to help corn and soybean farmers fight tough, resistant weeds. In this Managing for Profit, Ryan Tierney, Bayer's broad-acre herbicides segment manager, discusses the expected launch of Convinto™ herbicide next season. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über drohenden Ärger für Moderna, einen Kurskracher bei MongoDB und fiese Japan-Vibes. Außerdem geht es um Moderna, BioNTech, Novavax, Pfizer, GSK, MongoDB, Cleanspark, Coinbase, Robinhood, Strategy, Bitcoin, Ether, Bayer, Synopsis, Nvidia und The Magnum Ice Cream Company. Die aktuelle "Alles auf Aktien"-Umfrage findet Ihr unter: https://www.umfrageonline.com/c/mh9uebwm Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

En Capital Intereconomía hemos seguido en directo la apertura del Ibex 35 y del resto de bolsas europeas, en una jornada marcada por la publicación del dato de paro, que baja en 18.805 personas en noviembre. Este resultado y su impacto en el mercado laboral lo hemos analizado con Valentín Bote, director de Randstad Research. En el análisis de mercados, Pablo García (Divacons–Alphavalue) ha repasado una sesión condicionada por el dato de IPC, después de que Kocher (BCE) advirtiera de que no debe reaccionarse ante pequeñas variaciones. En EE. UU., la atención se centra en las cifras de JOLTS, el próximo PCE y las expectativas de tipos. También se ha comentado la postura del Banco de Inglaterra y la noticia de que la administración Trump respalda el intento de Bayer de limitar demandas por su herbicida Roundup, relacionadas con acusaciones de cáncer. El programa ha cerrado con el Consultorio de Bolsa junto a Javier Alfayate, gestor de fondos.

Repasamos nombres como Bayer, Airbus, LVMH, Campari, BNP Paribas e ISS. Con Josep Prats, gestor de fondos de Abante Asesores.

Audio roundup of selected biopharma industry content from Scrip over the business week ended November 28, 2025. In this episode: 2027 Medicare price cuts likely not as large as CMS estimates; Zai Lab leads DLL3 lung cancer ADC race; Phase II failure for J&J's Alzheimer's asset posdinemab; Bayer's positive Phase III data for asundexian in stroke; and Pfizer/Astellas's Padcev's first big win in bladder cancer study. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-R4RCDF2RXVGVHPEX2WQ7A3JVKU/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Dans cette vidéo, nous plongeons dans l'un des transferts les plus attendus de l'été : Xabi Alonso au Real Madrid ! Après avoir fait des merveilles avec le Bayer Leverkusen, le Basque prend les rênes du club Merengue dans une période de transition difficile. Adieu Carlo Ancelotti et ses Ligues des Champions à répétition… Place à un nouvel entraîneur, avec un style résolument moderne, offensif et très tactique. Mais la question demeure : Xabi Alonso a-t-il les épaules pour mener le Real Madrid au sommet de l'Europe à nouveau ?Dans cette vidéo, on revient sur sa carrière de joueur, son ascension comme entraîneur, son passage au Bayer Leverkusen et l'impact de ses idées footballistiques. Comment va-t-il gérer l'hégémonie du PSG et faire face à l'énorme pression du Real Madrid ? Le 3-4-2-1 qu'il adore va-t-il trouver sa place dans un club aussi prestigieux ? Et surtout, pourra-t-il gérer les egos des superstars comme Kylian Mbappé ?Allez, vamos, on plonge dans l'analyse d'un des coachs les plus prometteurs de la planète football !N'oubliez pas de vous abonner pour ne rien rater de cette aventure et des prochaines vidéos sur les grands coachs et transferts du moment !Pourquoi le Real Madrid peut détruire la carrière de Xabi AlonsoChapitre 1 : Un joueur fait pour devenir entraîneur 01:34Chapitre 2 : Une révolution au Bayer 03:17Chapitre 3 : Un mariage de raison ? 11:03 ---------------------------------------N'oublie pas de t'abonner, de liker, de commenter et de partager cette vidéo. Toutes les remarques sont bonnes à prendre, je n'hésiterai pas à utiliser tes retours pour nos prochaines vidéos. Active les notifications si tu ne veux rien louper sur Colinterview. Suis-moi sur toutes les plateformes :Facebook : https://bit.ly/3cJXvhfYouTube : https://bit.ly/3lb1yI1Instagram : https://bit.ly/3CR4zTCTikTok : https://bit.ly/3LJoaLqSnapchat : https://bit.ly/3cM5jPgTwitter : https://bit.ly/3s1yl5SSuis Oh My Goal sur toutes les plateformes :YouTube - Histoires FC - Oh My Goal : https://bit.ly/33Zo4OxYouTube - Oh My Goal - Actu Foot : https://bit.ly/3aY5gQcYouTube - Qu'est-il arrivé ? - Oh My Goal : https://bit.ly/3M4VtsmYouTube - Oh My Goal - Le Meilleur du Football : https://bit.ly/3sJdi7iYouTube - Oh My Goal - France - Shorts : https://bit.ly/3JE2A92Facebook : https://bit.ly/3nyCb2LInstagram : https://bit.ly/2S5jpEoTwitter : https://bit.ly/2Qyds2FTikTok : https://bit.ly/3xx8QKHOh My Goal : L'Hebdo | Snapchat : https://bit.ly/3xsREGd---------------------------------------© Oh My Goal

Today, we'll be tackling the future of prostate cancer care. We'll be reflecting on what prostate cancer care means in practice, how the way we think about the disease is shifting, and must continue to shift in the years ahead. Scientific advances have transformed treatment in recent years, yet the lived reality of prostate cancer still extends far beyond the clinic. The disease reshapes daily life, and may leave men and their families grappling with difficult choices about how best to manage it.  Dr. Güneş Taylor is joined by three key voices at the centre of this story, following the prostate cancer journey from diagnosis through to long-term management, and asking how patients and clinicians can work together to re-think what patient-centred care could mean in the years to come. This episode is brought to you in collaboration with Bayer, part of their Prostate Cancer Perspectives series.  PP-UN-ONC-GB-0168. November 2025 References Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263 (Prostate cancer is the second most common cancer in men and the fifth leading cause of cancer death worldwide) James D, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403(10437):1683–1722 (Each year, around 1.5 million men are diagnosed and nearly 400,000 lose their lives to the disease.1 And the numbers are rising. Diagnoses are projected to double from 1.4 million annually in 2020 to 2.9 million by 2040) Siegel RL, et al. Cancer statistics, 2022. Ca Cancer J Clin. 2022;72:7–33 (In the U.S., the proportion of men diagnosed with advanced-stage prostate cancer has doubled in recent years, due to increasing incidence of advanced-stage disease and changing guidelines regarding the prostate specific antigen screening test, implemented in the U.S. in 2012) Dodkins J, et al. Geographic, socioeconomic and demographic inequalities in the incidence of metastatic prostate cancer at time of diagnosis in England: a population based evaluation. BMJ Oncology. 2025;4:e000643 (In England, nearly one in five men only receive a diagnosis once their cancer has spread) Calvo-Schimmel A, et al. Supportive care interventions and quality of life in advanced disease prostate cancer survivors: An integrative review of the literature. Can Oncol Nurs J. 2021;31(4):412-429 (Advanced prostate cancer is often associated with long-term challenges leading to greater levels of unmet needs in supportive care) Learn more about your ad choices. Visit podcastchoices.com/adchoices

Gabor Steingart präsentiert das Pioneer Briefing.

Are multivitamins bad for you? How could that be? In this video, I'll share the truth about the multivitamin scam. Find out about the vitamins you should never take, supplements that don't work, and the harmful ingredients in your supplements. 0:00 Introduction: Multivitamins truth0:19 Harmful ingredients in supplements 1:45 Synthetic vs. natural vitamins 3:38 Do multivitamins really work?9:32 Natural vitamins and minerals11:17 Fake vitamins exposed! Many multivitamins are made with the cheapest, synthetic ingredients which could be doing more harm than good.The first ingredient in many multivitamins is often calcium carbonate, which is limestone! The first ingredient usually makes up the majority of the product. Magnesium oxide, another common ingredient, is very cheap and has the lowest absorption rate compared to other forms of magnesium. The term “natural” isn't regulated, so ingredients derived from sources such as petroleum and coal tar can be labeled as natural. In nature, vitamins don't exist alone; they are combined with other nutrients and cofactors, which are often missing when you take synthetic vitamins. Biochemistry can not work without cofactors. Although there are nutrients that are difficult to obtain in sufficient amounts from food, that doesn't mean they should be replaced with synthetic multivitamins.Maltodextrin is commonly used as a filler in vitamins and minerals. It's a highly refined industrial starch, classified as a complex carbohydrate, and spikes blood sugar more than sugar. Ascorbic acid is a synthetic part of the vitamin C complex. Approximately 90% is made in China from GMO corn and sulfuric acid. Many people have a genetic issue converting cyanocobalamin, a synthetic form of B12, and folic acid, a synthetic form of B9, into their active forms. This can cause negative side effects in 40% of the population.Almost all of the popular multivitamins are owned by Big Pharma, Big Food, Big Chemical, or large investment groups. For example, Centrum Silver is owned by Pfizer, and One a Day is owned by Bayer. Nature Made is owned by the same company that sells Abilify!Dr. Eric Berg DC Bio:Dr. Berg, age 60, is a chiropractor who specializes in Healthy Ketosis & Intermittent Fasting. He is the Director of Dr. Berg Nutritionals and author of the best-selling book The Healthy Keto Plan. He no longer practices, but focuses on health education through social media.Disclaimer: Dr. Eric Berg received his Doctor of Chiropractic degree from Palmer College of Chiropractic in 1988. His use of “doctor” or “Dr.” in relation to himself solely refers to that degree. Dr. Berg is a licensed chiropractor in Virginia, California, and Louisiana, but he no longer practices chiropractic in any state and does not see patients, so he can focus on educating people as a full-time activity, yet he maintains an active license. This video is for general informational purposes only. It should not be used to self-diagnose, and it is not a substitute for a medical exam, cure, treatment, diagnosis, prescription, or recommendation. It does not create a doctor-patient relationship between Dr. Berg and you. You should not make any change in your health regimen or diet before first consulting a physician and obtaining a medical exam, diagnosis, and recommendation. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition.